The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 1×
“Based on prospective randomised phase 3 trials, docetaxel at 75 mg/m at 3-wk intervals in combination with prednisone represents the cytotoxic regime of choice in men with CRPC resulting in a median survival benefit of 3 mo and a significant improvement of pain and QoL compared withmitoxantrone [71].”
BackgroundSipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Petrylak, D. P., Tangen, C. M., Hussain, M. H. A., Lara, P. N., Jones, J. A., Taplin, M. E., Burch, P. A., Berry, D., Moinpour, C., Kohli, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041318 · Cited by 3,665
EAU Guidelines on Prostate Cancer
Heidenreich, A., Aus, G., Bolla, M., Joniau, S., Matveev, V. B., Schmid, H. P., & Zattoni, F. (2008) · European Urology · doi:10.1016/j.eururo.2007.09.002 · Cited by 3,136
Self-citationRoach, M., Hanks, G., Thames, H., Schellhammer, P., Shipley, W. U., Sokol, G. H., & Sandler, H. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2006.04.029 · Cited by 2,749
Scher, H. I., Halabi, S., Tannock, I., Morris, M., Sternberg, C. N., Carducci, M. A., Eisenberger, M. A., Higano, C., Bubley, G. J., Dreicer, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4487 · Cited by 2,241
Saad, F., Gleason, D. M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., Chin, J. L., Vinholes, J. J., Goas, J. A., & Chen, B. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.19.1458 · Cited by 1,656
A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma
Crawford, E. D., Eisenberger, M. A., McLeod, D. G., Spaulding, J. T., Benson, R., Dorr, F. A., Blumenstein, B. A., Davis, M. A., & Goodman, P. J. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908173210702 · Cited by 1,464 · cited 1×
“Antiandrogens Short-term administration To reduce the risk of the ‘‘flare-up’’ phenomenon in patients with advanced metastatic disease who are to receive an LHRH agonist [89,90].”
BackgroundMessing, E. M., Manola, J., Sarosdy, M., Wilding, G., Crawford, E. D., & Trump, D. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912093412401 · Cited by 1,191
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
Scher, H. I., Beer, T. M., Higano, C. S., Anand, A., Taplin, M.-E., Efstathiou, E., Rathkopf, D., Shelkey, J., Yu, E. Y., Alumkal, J., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60172-9 · Cited by 1,063
Bubley, G. J., Carducci, M., Dahut, W., Dawson, N., Daliani, D., Eisenberger, M., Figg, W. D., Freidlin, B., Halabi, S., Hudes, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3461 · Cited by 977
Messing, E. M., Manola, J., Yao, J., Kiernan, M., Crawford, D., Wilding, G., di'SantAgnese, P. A., & Trump, D. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70700-8 · Cited by 893
Stephenson, A. J., Scardino, P. T., Kattan, M. W., Pisansky, T. M., Slawin, K. M., Klein, E. A., Anscher, M. S., Michalski, J. M., Sandler, H. M., Lin, D. W., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.9607 · Cited by 888
Klotz, L. H., BOCCON-GIBOD, L., Shore, N. D., Andreou, C., Persson, B., Cantor, P., Jensen, J.-K., Olesen, T. K., & Schröder, F. H. (2008) · British Journal of Urology · doi:10.1111/j.1464-410x.2008.08183.x · Cited by 666
Trock, B. J. (2008) · JAMA · doi:10.1001/jama.299.23.2760 · Cited by 657
(1997) · British Journal of Urology · doi:10.1046/j.1464-410x.1997.d01-6840.x · Cited by 654
Byar, D. P. (1973) · Cancer · doi:10.1002/1097-0142(197311)32:5<1126::aid-cncr2820320518>3.0.co;2-c · Cited by 597
Stephenson, A. J., Kattan, M. W., Eastham, J. A., Dotan, Z. A., Bianco, F. J., Lilja, H., & Scardino, P. T. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.0756 · Cited by 529
Hussain, M., Tangen, C. M., Higano, C., Schelhammer, P. F., Faulkner, J., Crawford, E. D., Wilding, G., Akdas, A., Small, E. J., Donnelly, B., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.4246 · Cited by 505
Danila, D. C., Morris, M. J., de Bono, J. S., Ryan, C. J., Denmeade, S. R., Smith, M. R., Taplin, M.-E., Bubley, G. J., Kheoh, T., Haqq, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.9259 · Cited by 410
Seidenfeld, J., Samson, D. J., Hasselblad, V., Aronson, N., Albertsen, P. C., Bennett, C. L., & Wilt, T. J. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-7-200004040-00009 · Cited by 398
Metabolic Complications of Androgen Deprivation Therapy for Prostate Cancer
Saylor, P. J., & Smith, M. R. (2009) · Journal of Urology · doi:10.1016/j.juro.2009.01.047 · Cited by 349
Sternberg, C. N., Petrylak, D. P., Sartor, O., Witjes, J. A., Demkow, T., Ferrero, J.-M., Eymard, J.-C., Falcon, S., Calabrò, F., James, N., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.1228 · Cited by 340
Studer, U. E., Whelan, P., Albrecht, W., Casselman, J., de Reijke, T., Hauri, D., Loidl, W., Isorna, S., Sundaram, S. K., Debois, M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7423 · Cited by 327
Tyrrell, C. J., Kaisary, A. V., Iversen, P., Anderson, J. B., Baert, L., Tammela, T., Chamberlain, M., Webster, A., & Blackledge, G. (1998) · European Urology · doi:10.1159/000019634 · Cited by 306
Kane, C. J., Amling, C. L., Johnstone, P. A. S., Pak, N., Lance, R. S., Thrasher, J. B., Foley, J. P., Riffenburgh, R. H., & Moul, J. W. (2003) · Urology · doi:10.1016/s0090-4295(02)02411-1 · Cited by 274
Giovacchini, G., Picchio, M., Coradeschi, E., Bettinardi, V., Gianolli, L., Scattoni, V., Cozzarini, C., Di Muzio, N., Rigatti, P., Fazio, F., et al. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1253-3 · Cited by 270
Calais da Silva, F. E. C., Bono, A. V., Whelan, P., Brausi, M., Marques Queimadelos, A., Martin, J. A. P., Kirkali, Z., Calais da Silva, F. M. V., & Robertson, C. (2009) · European Urology · doi:10.1016/j.eururo.2009.02.016 · Cited by 243
MOUL, J. W., WU, H., SUN, L., McLEOD, D. G., AMLING, C., DONAHUE, T., KUSUDA, L., SEXTON, W., O’REILLY, K., HERNANDEZ, J., et al. (2004) · Journal of Urology · doi:10.1097/01.ju.0000113794.34810.d0 · Cited by 224
The Efficacy and Complications of Salvage Cryotherapy of the Prostate
Pisters, L. L., von Eschenbach, A. C., Scott, S. M., Swanson, D. A., Dinney, C. P. N., Pettaway, C. A., & Babaian, R. J. (1997) · Journal of Urology · doi:10.1016/s0022-5347(01)65084-5 · Cited by 222
Murat, F.-J., Poissonnier, L., Rabilloud, M., Belot, A., Bouvier, R., Rouviere, O., Chapelon, J.-Y., & Gelet, A. (2009) · European Urology · doi:10.1016/j.eururo.2008.04.091 · Cited by 219
Kuhn, J.-M., Billebaud, T., Navratil, H., Moulonguet, A., Fiet, J., Grise, P., Louis, J.-F., Costa, P., Husson, J.-M., Dahan, R., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908173210701 · Cited by 209
Armstrong, A. J., Garrett-Mayer, E., de Wit, R., Tannock, I., & Eisenberger, M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2514 · Cited by 207
Abrahamsson, P.-A. (2010) · European Urology · doi:10.1016/j.eururo.2009.07.049 · Cited by 187
Heidenreich, A., Richter, S., Thüer, D., & Pfister, D. (2010) · European Urology · doi:10.1016/j.eururo.2009.02.041 · Cited by 185
Self-citationAndrogen Deprivation Therapy for the Treatment of Prostate Cancer: Consider Both Benefits and Risks
Isbarn, H., Boccon-Gibod, L., Carroll, P. R., Montorsi, F., Schulman, C., Smith, M. R., Sternberg, C. N., & Studer, U. E. (2009) · European Urology · doi:10.1016/j.eururo.2008.10.008 · Cited by 171
Perachino, M., Cavalli, V., & Bravi, F. (2009) · British Journal of Urology · doi:10.1111/j.1464-410x.2009.08814.x · Cited by 156
Hormonal therapy: historical perspective to future directions
McLeod, D. G. (2003) · Urology · doi:10.1016/s0090-4295(02)02393-2 · Cited by 155
Studer, U. E., Collette, L., Whelan, P., Albrecht, W., Casselman, J., de Reijke, T. M., Knönagel, H., Loidl, W. C., Isorna, S., Sundaram, S. K., et al. (2007) · European Urology · doi:10.1016/j.eururo.2007.12.032 · Cited by 151
Castration-Resistant Prostate Cancer: Current and Emerging Treatment Strategies
Lorenzo, G. D., Buonerba, C., Autorino, R., Placido, S. D., & Sternberg, C. N. (2010) · Drugs · doi:10.2165/10898600-000000000-00000 · Cited by 141
Early versus deferred androgen suppression in the treatment of advanced prostatic cancer
Wilt, T. J., Nair, B. P., MacDonald, R. H., & Rutks, I. (2001) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003506 · Cited by 138
de Leval, J., Boca, P., Youssef, E., Nicolas, H., Jeukenne, M., Seidel, L., Bouffioux, C., Coppens, L., Bonnet, P., Andrianne, R., et al. (2002) · Clinical Prostate Cancer · doi:10.3816/cgc.2002.n.018 · Cited by 136
Schmitt, B. P., Wilt, T. J., Schellhammer, P. F., DeMasi, V., Sartor, O. A., Crawford, E. D., & Bennett, C. L. (2001) · Urology · doi:10.1016/s0090-4295(00)01086-4 · Cited by 131
Schröder, F. H., Kurth, K., Fosså, S. D., Hoekstra, W., Karthaus, P., de Prijck, L., & Collette, L. (2008) · European Urology · doi:10.1016/j.eururo.2008.09.008 · Cited by 121
Warmuth, M., Johansson, T., & Mad, P. (2010) · European Urology · doi:10.1016/j.eururo.2010.09.009 · Cited by 120
Role of Androgen Deprivation Therapy for Node-Positive Prostate Cancer
Wong, Y., Freedland, S. J., Egleston, B. L., Hudes, G. R., Schwartz, J. S., & Armstrong, K. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.2042 · Cited by 113
Manni, A., Bartholomew, M. J., Caplan, R. J., Boucher, A. E., Santen, R. J., Lipton, A., Harvey, H., Simmonds, M. A., White-Hershey, D., & Gordon, R. A. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.9.1456 · Cited by 111
Metabolic sequelae associated with androgen deprivation therapy for prostate cancer
Faris, J. E., & Smith, M. R. (2010) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3283391fd1 · Cited by 105
Eymard, J., Oudard, S. M., Gravis, G., Ferrero, J.-., Théodore, C., Joly, F., Priou, F., Krakowski, I., Zannetti, A., Thill, L., et al. (2010) · British Journal of Urology · doi:10.1111/j.1464-410x.2010.09296.x · Cited by 99
Slovin, S. F., Wilton, A. S., Heller, G., & Scher, H. I. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1668 · Cited by 92
Breeuwsma, A. J., Pruim, J., van den Bergh, A. C. M., Leliveld, A. M., Nijman, R. J. M., Dierckx, R., & de Jong, I. J. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.04.090 · Cited by 90
Westphalen, A. C., Coakley, F. V., Roach, M., McCulloch, C. E., & Kurhanewicz, J. V. (2010) · Radiology · doi:10.1148/radiol.10092314 · Cited by 88
Loriot, Y., Massard, C., Gross‐Goupil, M., Palma, M. D., Escudier, B. J., Bossi, A., Chauchereau, A., & Fizazi, K. S. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.04.010 · Cited by 87
The role of intermittent androgen deprivation in prostate cancer
BOCCON-GIBOD, L., Hammerer, P. G., Stephan Madersbacher, A., Mottet, N., Prayer‐Galetti, T., & Tunn, U. W. (2007) · British Journal of Urology · doi:10.1111/j.1464-410x.2007.07053.x · Cited by 68
Self-citationMoróte, J., Esquena, S., Junquera, J. M. A., Trilla, E., Cecchini, L., Raventos, C. X., Catalán, R., & Reventós, J. (2006) · Urologia Internationalis · doi:10.1159/000093907 · Cited by 65
Tyrrell, C., Denis, L., Newling, D., Soloway, M. S., Channer, K. S., Cockshott, I. D., & on behalf of the ‘Casodex’ Study Group (1998) · European Urology · doi:10.1159/000019526 · Cited by 62
Testosterone Measurement in Patients with Prostate Cancer
Schulman, C. C., Irani, J., Moróte, J., Schalken, J. A., Montorsi, F., Chłosta, P. L., & Heidenreich, A. (2010) · European Urology · doi:10.1016/j.eururo.2010.04.001 · Cited by 52
Self-citationInterval to Testosterone Recovery After Hormonal Therapy for Prostate Cancer and Risk of Death
D'Amico, A. V., Chen, M., Renshaw, A. A., Loffredo, M. J., & Kantoff, P. W. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.10.082 · Cited by 49
A systematic review and meta-analysis of bone metabolism in prostate adenocarcinoma
Neto, A. S., Tobias‐Machado, M., Esteves, M. A., Senra, M. D., Wroclawski, M. L., Fonseca, F. L., dos Reis, R. B., Pompeo, A. C., & del Giglio, A. (2010) · BMC Urology · doi:10.1186/1471-2490-10-9 · Cited by 44
Is there a role for antiandrogen monotherapy in patients with metastatic prostate cancer?
Kaisary, A. V., Iversen, P., Tyrrell, C., Carroll, K., & Morris, T. (2001) · Prostate Cancer and Prostatic Diseases · doi:10.1038/sj.pcan.4500531 · Cited by 38
Role of targeted therapy in the treatment of advanced prostate cancer
Fizazi, K. S., Sternberg, C. N., Fitzpatrick, J. M., Watson, R. W. G., & Tabesh, M. (2010) · British Journal of Urology · doi:10.1111/j.1464-410x.2010.09236.x · Cited by 36
Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer
Moul, J. W. (2009) · Cancer · doi:10.1002/cncr.24393 · Cited by 31
Ryan, C. J., Efstathiou, E., Smith, M. R., Taplin, M. E., Bubley, G. J., Logothetis, C. J., Kheoh, T. S., Haqq, C., Molina, A., & Small, E. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.5046 · Cited by 24
Heidenreich, A., Semrau, R., Thüer, D., & Pfister, D. J. K. P. (2008) · Der Urologe · doi:10.1007/s00120-008-1726-1 · Cited by 15
Self-citationAdditional therapy for high-risk prostate cancer treated with surgery: what is the evidence?
Morgan, S. C., & Dearnaley, D. P. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.60 · Cited by 8
Ohlmann, C., Markert, E., Gerharz, M., Dienes, H., Stöckle, M., Engelmann, U. H., & Heidenreich, A. (2009) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2009.09.010 · Cited by 7
Self-citation
Cited by
Heidenreich, A., Bastian, P. J., Bellmunt, J., Bolla, M., Joniau, S., van der Kwast, T., Mason, M., Matveev, V., Wiegel, T., Zattoni, F., et al. (2014) · European Urology · doi:10.1016/j.eururo.2013.11.002 · Cited by 1,341
Self-citationPROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
Raina, K., Lu, J., Qian, Y., Altieri, M., Gordon, D., Rossi, A. M. K., Wang, J., Chen, X., Dong, H., Siu, K., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521738113 · Cited by 852
PROTACs: great opportunities for academia and industry
Sun, X., Gao, H., Yang, Y., He, M., Wu, Y., Song, Y., Tong, Y., & Rao, Y. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0101-6 · Cited by 613
Hofman, M. S., Hicks, R. J., Maurer, T., & Eiber, M. (2018) · RadioGraphics · doi:10.1148/rg.2018170108 · Cited by 383
Schrader, A. J., Boegemann, M., Ohlmann, C.-H., Schnoeller, T. J., Krabbe, L.-M., Hajili, T., Jentzmik, F., Stoeckle, M., Schrader, M., Herrmann, E., et al. (2014) · European Urology · doi:10.1016/j.eururo.2013.06.042 · Cited by 284
Metadata
- Authors
- Mottet, N., Bellmunt, J., Bolla, M., Joniau, S., Mason, M., Matveev, V., Schmid, H.-P., Van der Kwast, T., Wiegel, T., Zattoni, F., & Heidenreich, A.
- Venue
- European Urology
- Publisher
- Elsevier BV
- Published
- 2011-04
- Volume
- 59
- Issue
- 4
- Pages
- 572-583
- ISSN
- 0302-2838 (ISSN-L)
- OpenAlex
- W4293409513
- Cited by
- 493
- References
- 66
- FWCI
- 79.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.